
LUNCHEON PRESENTER PROFILES



John M. Maraganore, PhD

CEO, Alnylam Pharmaceuticals

John M. Maraganore, PhD, has served as a member of Alnylam's Pharmaceuticals' Board of Directors since November 2011. Since 2002, Dr. Maraganore has served as the Chief Executive Officer and as a Director of Alnylam Pharmaceuticals, Inc., a publicly-traded biopharmaceutical company. From 2002 to 2007, Dr. Maraganore served as President of Alnylam. From 2000 to 2002, Dr. Maraganore served as Senior Vice President, Strategic Product Development with Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now Takeda Oncology). Before Millennium, he served as Director of molecular biology and Director of market and business development at Biogen Inc. (formerly known as Biogen Idec), or Biogen. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., a biotechnology company, and The Upjohn Company, a pharmaceutical manufacturing company.

Dr. Maraganore was formerly a Director of bluebird bio, Inc., a publicly-traded biopharmaceutical company. In addition, he was formerly a venture partner at Third Rock Ventures, L.P., where he participated in a limited capacity focusing on guiding strategy for Third Rock and its portfolio of companies, and was formerly chairman of the Board of Directors of Regulus Therapeutics, Inc., a publicly-traded company. He is also a member of the Immunology Advisory Council of Harvard Medical School and chair of the Biotechnology Innovation Organization. Dr. Maraganore holds a Master of Science and a Doctor of Philosophy in biochemistry and molecular biology from the University of Chicago, and a Bachelor of Arts in biological sciences also from the University of Chicago.